Total Payments
$19,358
2024 Payments
$2,636
Companies
43
Transactions
773
Medicare Patients
16,570
Medicare Billing
$2.1M
Payment Breakdown by Category
Food & Beverage$13,726 (70.9%)
Other$5,550 (28.7%)
Education$45.49 (0.2%)
Travel$36.45 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,726 | 766 | 70.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,550 | 3 | 28.7% |
| Education | $45.49 | 3 | 0.2% |
| Travel and Lodging | $36.45 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,608 | 162 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,795 | 129 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $966.77 | 76 | $0 (2024) |
| Amgen Inc. | $952.34 | 62 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $949.04 | 32 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $818.90 | 40 | $0 (2024) |
| PFIZER INC. | $720.16 | 35 | $0 (2024) |
| Novo Nordisk Inc | $634.58 | 26 | $0 (2024) |
| Merck Sharp & Dohme LLC | $619.56 | 28 | $0 (2024) |
| Abbott Laboratories | $553.10 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,636 | 108 | E.R. Squibb & Sons, L.L.C. ($502.18) |
| 2023 | $2,396 | 112 | AstraZeneca Pharmaceuticals LP ($493.07) |
| 2022 | $1,732 | 113 | Novartis Pharmaceuticals Corporation ($267.80) |
| 2021 | $1,332 | 69 | CVRx, Inc. ($148.47) |
| 2020 | $689.74 | 34 | Amarin Pharma Inc. ($240.16) |
| 2019 | $1,724 | 102 | PFIZER INC. ($284.06) |
| 2018 | $1,039 | 87 | Novartis Pharmaceuticals Corporation ($216.89) |
| 2017 | $7,809 | 148 | Novartis Pharmaceuticals Corporation ($6,317) |
All Payment Transactions
773 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $9.02 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Obesity | ||||||
| 12/03/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Cardiology | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $124.09 | General |
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $12.92 | General |
| Category: Cardiovascular | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/06/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Cardiology | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.00 | General |
| Category: Cardiovascular | ||||||
| 10/29/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Obesity | ||||||
| 10/28/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Cardiology | ||||||
| 10/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/24/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Cardiology | ||||||
| 10/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $6.15 | General |
| Category: DIABETES | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: Obesity | ||||||
| 10/15/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $17.33 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/14/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Obesity | ||||||
| 09/24/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $109.56 | General |
| 09/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $7.33 | General |
| Category: DIABETES | ||||||
| 09/13/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.45 | General |
| Category: Cardiovascular | ||||||
| 09/12/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 4,458 | 6,856 | $850,693 | $521,215 |
| 2022 | 32 | 3,970 | 6,238 | $881,764 | $573,660 |
| 2021 | 31 | 4,136 | 6,358 | $885,659 | $564,094 |
| 2020 | 28 | 4,006 | 6,589 | $788,248 | $473,295 |
Total Patients
16,570
Total Services
26,041
Medicare Billing
$2.1M
Procedure Codes
130
All Medicare Procedures & Services
130 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 588 | 951 | $188,298 | $131,546 | 69.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 768 | 1,205 | $180,990 | $120,319 | 66.5% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 81 | 81 | $86,191 | $61,175 | 71.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 238 | 241 | $90,375 | $39,341 | 43.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 118 | 272 | $34,610 | $26,964 | 77.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 51 | 51 | $30,600 | $19,347 | 63.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 899 | 1,609 | $56,315 | $18,659 | 33.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 162 | 264 | $26,400 | $17,337 | 65.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 76 | 78 | $17,550 | $11,320 | 64.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 142 | 166 | $16,766 | $9,752 | 58.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 20 | 44 | $12,984 | $7,875 | 60.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $9,074 | $6,348 | 70.0% |
| 93924 | Ultrasound of leg arteries at rest and after exercise | Office | 2023 | 45 | 45 | $8,730 | $5,974 | 68.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 523 | 780 | $23,400 | $5,198 | 22.2% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Office | 2023 | 66 | 66 | $6,600 | $4,862 | 73.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $9,175 | $4,663 | 50.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 22 | 88 | $5,311 | $4,164 | 78.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 66 | 66 | $9,900 | $3,777 | 38.1% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 51 | 53 | $4,694 | $3,604 | 76.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 52 | 52 | $5,980 | $2,791 | 46.7% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 38 | 143 | $4,273 | $2,782 | 65.1% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 46 | 97 | $3,529 | $2,207 | 62.5% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 55 | 114 | $3,400 | $2,084 | 61.3% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 17 | 50 | $2,150 | $1,693 | 78.7% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Office | 2023 | 66 | 66 | $2,310 | $1,615 | 69.9% |
About Dr. Kenneth Harris, MD
Dr. Kenneth Harris, MD is a Cardiovascular Disease healthcare provider based in Neptune, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1861492027.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Harris, MD has received a total of $19,358 in payments from pharmaceutical and medical device companies, with $2,636 received in 2024. These payments were reported across 773 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($13,726).
As a Medicare-enrolled provider, Harris has provided services to 16,570 Medicare beneficiaries, totaling 26,041 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 130 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Neptune, NJ
- Active Since 07/28/2005
- Last Updated 09/26/2012
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1861492027
Products in Payments
- ENTRESTO (Drug) $7,203
- ELIQUIS (Drug) $1,375
- XARELTO (Drug) $966.77
- Repatha (Biological) $700.80
- JARDIANCE (Drug) $637.19
- VERQUVO (Drug) $619.56
- Vascepa (Drug) $540.63
- VYNDAQEL (Drug) $465.96
- CAMZYOS (Drug) $420.85
- LEQVIO (Drug) $404.57
- Barostim Neo System (Device) $316.48
- PRALUENT (Drug) $271.18
- Ozempic (Drug) $257.74
- Corlanor (Drug) $251.54
- Endurant (Device) $239.87
- BRILINTA (Drug) $219.69
- LOKELMA (Drug) $219.57
- MULTAQ (Drug) $202.40
- FARXIGA (Drug) $198.73
- NEXLETOL (Drug) $194.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Neptune
Dr. Renato Apolito, M.d, M.D
Cardiovascular Disease — Payments: $30,948
Cardiovascular Disease $30,948
Dr. Ravi Diwan, Md, MD
Cardiovascular Disease — Payments: $26,864
Cardiovascular Disease $26,864
Laith Zamel, M.d, M.D
Cardiovascular Disease — Payments: $23,335
Cardiovascular Disease $23,335
James Orlando, M.d, M.D
Cardiovascular Disease — Payments: $23,239
Cardiovascular Disease $23,239
Maurice Weiss, M.d, M.D
Cardiovascular Disease — Payments: $15,297
Cardiovascular Disease $15,297
Edward Choi, M.d, M.D
Cardiovascular Disease — Payments: $15,082
Cardiovascular Disease $15,082